Aduro Biotech Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meetin...
October 02 2019 - 3:05PM
Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage
biopharmaceutical company focused on developing therapies targeting
the Stimulator of Interferon Genes (STING) and A Proliferation
Inducing Ligand (APRIL) pathways for the treatment of cancer,
autoimmune and inflammatory diseases, today announced that two
abstracts have been accepted for presentation at the Society for
Immunotherapy of Cancer 34th Annual Meeting (SITC 2019) in National
Harbor, MD from November 6 – 10, 2019. The abstracts, which will be
presented in a poster session, include a clinical trial in progress
description of the Phase 2 study of ADU-S100 (MIW815) in
combination with KEYTRUDA® (pembrolizumab) as a first-line
treatment for recurrent or metastatic head and neck squamous cell
carcinoma (HNSCC), as well as nonclinical data on the role of
TNF-alpha signaling on STING agonists.
Details of the posters are as follows:
Poster
396: |
|
A Phase 2
Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults
with Head and Neck Cancer |
Category: |
|
Clinical Trial In
Progress |
Date/Time: |
|
Saturday, November 9, 2019,
7:00 AM – 8:30 PM ET |
Location: |
|
Poster Hall (Prince George
AB) |
|
|
|
Poster 660: |
|
TNF-alpha suppresses the
Immunogenicity of STING-agonists |
Category: |
|
Immune-stimulants and immune
modulators |
Date/Time: |
|
Saturday, November 9, 2019,
7:00 AM – 8:30 PM ET |
Location: |
|
Poster Hall (Prince George
AB) |
To view these abstracts, please visit the SITC 2019 website
located at https://www.sitcancer.org/2019/home.
About Aduro Aduro Biotech, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies that are designed to
harness the body’s natural immune system for the treatment of
patients with challenging diseases. Aduro’s product candidates in
the Stimulator of Interferon Genes (STING) and A Proliferation
Inducing Ligand (APRIL) pathways are being investigated in cancer,
autoimmune and inflammatory diseases. ADU-S100 (MIW815), which
potentially activates the intracellular STING receptor for a potent
tumor-specific immune response, is being evaluated in patients with
cutaneously accessible metastatic solid tumors or lymphomas.
BION-1301, a first-in-class humanized IgG4 monoclonal antibody that
fully blocks APRIL binding to both the BCMA and TACI receptors, is
being evaluated in IgA nephropathy. Aduro is collaborating with a
number of leading global pharmaceutical companies to help expand
and drive its product pipeline. For more information, please visit
www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include statements
regarding our intentions or current expectations concerning, among
other things, the potential for our therapies, the progress of our
clinical programs and our ability to expand and drive our product
pipeline alone or with collaborators. In some cases, you can
identify these statements by forward-looking words such as “may,”
“will,” “continue,” “anticipate,” “intend,” “could,” “project,”
“expect” or the negative or plural of these words or similar
expressions. Forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that
could cause actual results and events to differ materially from
those anticipated, including, but not limited to, early or
preliminary clinical trial results may not be predictive of future
results, our history of net operating losses and uncertainty
regarding our ability to achieve profitability, our ability to
develop and commercialize our product candidates, our ability to
use and expand our technologies to build a pipeline of product
candidates, our ability to obtain and maintain regulatory approval
of our product candidates, our ability to operate in a competitive
industry and compete successfully against competitors that have
greater resources than we do, our reliance on third parties, and
our ability to obtain and adequately protect intellectual property
rights for our product candidates. We discuss many of these
risks in greater detail under the heading “Risk Factors” contained
in our quarterly report on Form 10-Q for the quarter ended June 30,
2019, which is on file with the Securities and Exchange Commission.
Any forward-looking statements that we make in this press release
speak only as of the date of this press release. We assume no
obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
Contact: |
Noopur
Liffick |
510-809-2465 |
investors@aduro.com |
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jul 2023 to Jul 2024